New targeted drug may improve lymphoma treatment
NCT ID NCT07372365
First seen Jan 31, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This study tests a new approach for people with untreated marginal zone lymphoma, a slow-growing blood cancer. Participants first get a short course of standard chemotherapy, then a targeted drug called orelabrutinib to keep the cancer under control. The goal is to see if this combination improves response rates and delays the cancer's return. About 23 people will take part, and they will be closely monitored for side effects and treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orelabrutinib (a targeted drug) combined with R-CHOP chemotherapy and rituximab
What this could lead to
If successful, this could offer a more effective and less toxic treatment plan for people with newly diagnosed marginal zone lymphoma, potentially improving long-term disease control.
What could go wrong
This is a small, early-phase study with only 23 participants, so results may not apply to everyone. The drug may cause side effects, and the treatment may not work better than current options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.